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Chapter 1: Herbal Supplements – A Personal Tradition
Growing up as a Vietnamese-American, I am well versed in the idea of cultural
differences. Early on, I realized that culture permeates everything – including the way we
approach our health. In many ways, the dichotomy between Western and Eastern
medicine mimics the contrast between the different cultures. I experienced this first hand
with my grandma. To this day, her medicine cabinet remains stock full. Granted, about
half of this cabinet is filled with prescription medications, over the counter drugs, and
multi-vitamins. However, the other half is filled with herbal supplements. Many of these
herbal supplement bottles are brightly decorated with CGI images of human anatomy or
with a photo of an unspecified plant and most, if not all, contain non-descriptive names
such as “Kidney” or “Livertox.” The vague descriptions and the limited ingredients list
raised a lot of questions about the safety and efficacy of these supplements. While I
remained wary and skeptical about these herbal remedies, I became aware of the wide
range of possible physiological effects of these supplements. My grandma introduced me
to a different side of medicine, one often ignored by researchers and providers.
While traditional western medicine often excludes alternative or Eastern
medicine, many people worldwide rely on complementary alternative medicine (CAM)
which can include herbal supplements, dietary supplements, acupuncture, among other
therapies. A significant number of women worldwide use these natural therapies at least
once during their reproductive age. Interestingly, women who use CAM and herbal
10

remedies tend to be 31-40 years old with higher education levels and higher income
levels, (Kennedy, Lupattelli, Koren, & Nordeng, 2013). The uptick in alternative
medicine can be attributed to a multitude of different factors. Women often cite that
alternative medicine techniques such as herbal medication promotes holistic health care
by introducing the use of natural products, a method they prefer to the clinical side of
Western medicine. Herbal therapy proponents hold that these natural therapies exist in a
separate category compared to pharmaceutical or OTC drugs and appear to be
synonymous to safe (Warriner et al., 2014). Using the power of the internet and personal
testimonies, the surge in CAM and herbal supplement use continues into the current day.
Currently, there are thousands of herbal supplements readily available to the
general public and due to a little niche in FDA regulation, these supplements remain
largely unregulated and unstandardized. In comparison, thousands of over the counter
medications and pharmacological drugs exist, but many of these substances may be
limited via prescriptions. Given their accessibility and increasing popularity, many
women take a combination of pharmacological drugs and herbal supplement. The use of
one or both methods are evident during pregnancy because women experience a whole
slew of different symptoms. However, unregulated combinations result in potential herbal
and pharmacological interactions, leading to a host of unintended physiological and
biochemical effects on the maternal and fetal system. I believe that pregnant women need
a comprehensive guide on how to navigate this complicated system. Women should be
aware of the benefits, adverse side effects, and the possible interactions of both
11

pharmacological methods and herbal remedies, which allows them to make an informed
decision on the course of their healthcare.
Throughout the course of this thesis, I will comment on current Federal Food and
Drug Administration (FDA) guidelines on the regulation of herbal supplements and
compare them to international guidelines. I will elucidate on how gaps in these
regulations can be detrimental to the health of patients and use this as a platform to
introduce an extensive guide denoting the major biochemical changes occurring
antepartum and postpartum as an explanation for symptoms often experienced during
pregnancy. I will then use this as a background to detail the mechanism of the active
ingredients in these supplements and comment on the effectiveness of the relating FDA
regulations. I hope that this thesis will help raise awareness about common herbal
supplements and serve as a resource grounded in scientific facts for women looking into
alternative medicine during pregnancy.

12
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Chapter 2: Differential Regulation of Pharmaceutical Drugs and Herbal
Supplements Creates a Public Health Hazard

International Laws and Regulation
The use of herbal supplements originated in the East, and currently,
countries all over the world employ alternative medicine, especially the use of herbal
supplements to treat certain ailments. In such a global society, the exchange of data
information and regulatory remains a major part of international communication. While
the World Health Organization (WHO) isn’t an official regulator of herbal medication
and supplements, this association serves as a hub for information exchange regarding
different national regulations. The WHO also supports the International Regulatory
Cooperation for Herbal Medication (IRCH), an organization developed in 2006 by
several countries who expressed interest in sharing research and regulatory issues. The
IRCH, whose main purpose includes providing a global network of regulatory authorities
responsible for regulating and promoting herbal supplements, includes 33 national and
regional members who conduct annual meetings to discuss issues revolving around
herbal medication and complementary medicine (Alostad, Steinke, & Schafheutle, 2018).

From the importation of herbal plants and supplements to their distribution, the
regulation of these substances takes on different faces across the globe. For example,
Germany has a well-established regulatory and registration system that even predates the
policy enforced by the European Union. As a result, some reports suggest that
14

approximately 70% of German physicians claim to feel confident in prescribing herbal
medications to their patients. In contrast, India lacks a reliable regulation system. The
mainframe of their system relies on poorly enforced policies and manufacturers can take
advantage of many loopholes (Alostad et al., 2018). In comparison to many other
countries, the United States employs a rather simplistic and broad approach towards
regulation of these substances. Countries such as Germany and the UK have employed a
more structured and reasoned system for registering herbal supplements and medication
as seen in Figure 1. The United States differs from the structure and order of these
different regulation systems in three main categories: evidence for safety and efficacy as
well as registration requirements.

15

Figure 1. Summary comparison of herbal medication registration and regulation requirements
set by the different regulatory agencies of the UK, USA, United Arab Emirates, Germany, and the
Kingdom of Bahrain. This table looked at the differences between evidence requirements and
labeling requirements between these countries. Figure adapted from Alostad, A. H., Steinke, D.
T., & Schafheutle, E.I. (2018). International Comparison of Five Herbal Medicine Registration
Systems to Inform Regulation Development: the United Kingdom, United States of America,
United Arab Emirates and the Kingdom of Bahrain. Pharmaceutical Medicine, 32 (1), 39-49.
Doi:10.1007/s40290-018-0223-0.
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Perhaps most notably, as Figure 1 denotes, the regulatory authority in the U.S. or
the FDA requires no evidence for safety, efficacy, or efficiency for dietary and herbal
supplements. Conversely, many other countries require herbal medication to adhere to
pre-marketing registration laws including laboratory standards, manufacturing standards,
and storage requirements. Without the requirement for pre-marketing evaluation, the
United States sets up a system where FDA intervention doesn’t begin until the herbal
supplement enters the market and proves to be detrimental to patient health. This almost
backward approach disavows any change for preventative regulation of herbal
medications and leaves the door open for loopholes that manufacturers can take
advantage of. The US notably requires no evidence from herbal manufactures or sellers
other than a disclaimer on the box or bottle. In contrast, all of the other 4 countries used
in this study require at least some form of validation for each of the main registration
components.

Secondly, the United States employs different registration requirements compared
to its international counterparts. In countries apart of the European Union, herbal
supplements and medication registered by the one-member state will be accepted by all
other states in the union. However, under this directive, each member’s regulatory agency
will employ pre-marketing checks and quality assessment. This system tried to ensure
that each country can benefit from these herbal medications while also maintaining the
proper quality assessments. Countries such as Germany also consider traditional usage as
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evidence of efficacy, thus reducing the need for extensive clinical trials to validate their
efficacy (Alostad et al., 2018). In the U.S., herbal supplements can make certain
nutritional support claims, however, should a supplement claim to treat or cure a disease,
it will be regarded as a botanical drug and undergo the same rigid requirements and
standards imposed on conventional drugs. Because of this, between 2004 and 2013, only
two botanical drugs have received FDA approval out of over 400 applicants (Avigan,
Mozersky, & Seeff, 2016). Given the drastic differences between FDA policies and
foreign policies, we will take a closer look into the specific policies that regulate dietary
and herbal supplements.

History of FDA Regulation
The FDA is a regulatory agency for food and drugs in the U.S. Established by
Harvey Washington Wiley, the head of the Bureau of Chemistry in the Department of
Agriculture, this agency enforced regulations regarding the safety and quality of food
products and pharmaceutical drugs. Prior to its establishment, the 1800s gave rise to a
corrupt food and drug market. Many products sold during this era boasted claims with no
backing and most commodities failed to disclose all of the ingredients in the product
(Seamon & Clauson, 2005). The height of the crisis came in the form of the 1906 novel
The Jungle, where Upton Sinclair elucidated the adulteration issues in the food industry,
particularly the meat industry. With the public’s attention focused on the unsanitary
conditions of food preparation and the danger of mislabeling, Congress passed the Pure
18

Food and Drug Act, which prohibited the misbranding and adulteration of food and drug
products. In 1938, the government passed the FDCA (Food, Drug, and Cosmetic Act) to
further elucidate the regulations placed on manufacturers and distributors. Under this act,
no new drug can be marketed until it passes safety benchmarks set by the FDA and labels
are required to contain adequate instructions and warnings. The 1938 bill also broadened
the scope of the FDA to encompass cosmetics and therapeutic devices and therapies. Just
two years after the enactment of this policy, the FDA issued dozens of safety warnings
against various drug products and even deemed some products unsafe for distribution
(Chhabra, Kremzner, & Kiliany, 2005). This bill creates the foundation for current food
and drug regulation, and the FDA continues to modify and adjust its regulatory principles
and systems today (Spies, 2006).
DSHEA: Distinguishing Herbal Supplements from Pharmacological Drugs
On October 25, 1994, President Bill Clinton passed the Dietary Supplement
Health Education Act of 1994 (DSHEA) to establish standards for dietary and herbal
supplements. The act starts in Section 3 by defining dietary and herbal supplements by
law through a very rigid and specific definition:
“(1) means a product (other than tobacco) intended to supplement the diet that
bears or contains one or more of the following dietary ingredients:
▪
▪
▪
▪

“(A) a vitamin;
“(B) a mineral;
“(C) an herb or other botanical;
“(D) an amino acid;
19

▪
▪

“(E) a dietary substance for use by man to supplement the diet by
increasing the total dietary intake; or
“(F) a concentrate, metabolite, constituent, extract, or combination
of any ingredient described in clause (A), (B), (C), (D), or (E)”
(FDA, 1994)

This act requires that all substances adhering to the definition of the dietary or herbal
supplement must comply with some regulations. For example, the FDA prohibits
distribution of adulterated or misbranded products and manufacturers must comply with
the Current Good Manufacturing Practices as defined by the FDA (Curry, Schaffer, &
Yoon, 2016).
However, under these conditions, these substances are automatically placed in
their own category, removing them from the regulations imposed on pharmaceutical
drugs. In fact, this act mandates that dietary supplement regulation mirrors that of a
specialized food group rather than a drug. By placing dietary and herbal supplements
under the broad umbrella of food regulation, these substances are excluded from the
stringent requirements that govern pharmaceutical drugs. The most prominent exclusion
revolves around the notion of premarket approval and pre-clinical data and trials.
Pharmaceutical drugs, before even approaching distribution in the market, are required to
provide sufficient data on the effectiveness and the potential side effects of the product to
gain premarket approval by the FDA. A significant amount of research and thorough
clinical trials predate the release of any modern drug. In contrast, the DSHEA dictates
that manufacturers are responsible for determining the safety of the product and its claims
(Spies, 2006). Thus, the burden lies with the FDA to provide proof that a dietary or
20

herbal supplement poses significant harm before the substance can be removed from the
market.

The DSHEA also allows dietary supplements to make certain nutritional support
claims. Taken from the FDA:
“(A) the statement claims a benefit related to a classical nutrient
deficiency disease and discloses the prevalence of such disease in the
United States, describes the role of a nutrient or dietary ingredient
intended to affect the structure or function in humans, characterizes the
documented mechanism by which a nutrient or dietary ingredient acts to
maintain such structure or function, or describes general well-being from
consumption of a nutrient or dietary ingredient (FDA, 1994).
In other words, under this section of the DSHEA, there are four main claims that dietary
supplements can make without causing the FDA to consider the product as a drug. To
make these claims, the seller must provide data supporting the claims and to ensure that
these claims contain no false or misleading information. The FDA also requires all
dietary and herbal supplement labels to bear the disclaimer, “This statement has not been
evaluated by the Food and Drug Administration. This product is not intended to diagnose,
treat, cure, or prevent any disease” (FDA, 1994; Spies, 2006). Despite the disclaimer, this
section gives dietary supplements a looser leash, allowing them to publish certain types
of claims that regimented drugs are prohibited from making. For example, a seller can
claim that cranberry supplements can increase the acidity of urine to improve urinary
tract function, but they cannot claim that these supplements decrease the likelihood of
urinary tract infections, nor can they claim that these supplements prevent an individual
21

from contracting a UTI. By changing the wording of the claim, herbal and dietary
supplements can publish and market certain nutritional support claims without adhering
to the governing factors of traditional drugs (Spies, 2006).

Criticisms of DSHEA: Biochemical Impact of Active Ingredients and Potential Side
Effects
Despite their seemingly benign reputation, herbal supplements rely on active
chemical compounds extracted from plants to induce physiological changes in the body,
which mimics the mechanism that drugs employ. Especially in the presence of certain
active compounds in pharmaceutical drugs, herbal products can have pharmacodynamic
interactions that result in adverse side effects. Thus, herbal medications can also pose a
significant health risk, in the right conditions and should be regulated as such. While the
current policies in place keep the price of herbal medications significantly lower
compared to conventional drugs, the almost hands-off approach significantly increases
risk towards the consumers due to poorly defined and manufacturing processes. Many
herbal compounds have been proven to have pharmacodynamic interactions with the
active components in commonly used conventional drugs. For example, St. John’s Wort,
an herbaceous perennial plant commonly used for the treatment of depression, has been
proven to interact with a number of drugs, including immunosuppressants,
contraceptives, anticoagulants and more. St. John’s Wort has been found to significantly
reduce the pharmacological effect of warfarin when taken in combination. While many of
these herb-drug interactions exist, poor regulation and research behind these adverse side
22

effects hinder the scientific process in gathering accurate data and implementing the
appropriate response to minimize consumer risk.

While the FDA seems to be the hallmark for conventional drug regulation, its
approach to herbal medication leaves the door open to many different loopholes that
might increase the health risk for many consumers. Based on the analysis of the DSHEA,
the main regulatory policy enforced by the US, herbal supplements receive more lax
regulations compared to their drug counterparts. Without rigorous screening and strict
manufacturing restrictions, herbal medication manufacturers require less testing and the
overall process from development to distribution remains less regulated. As a result,
many of the herbal supplements and medications on the market may pose a significant
health risk towards consumers as the quality of the ingredients that many sellers claim to
be present are not properly accessed. In fact, a study conducted by researchers in Toronto
analyzing the ingredients contained in 44 different herbal supplements sold in the United
States and Canada revealed that less than half of these supplements contained any herbal
substances disclosed on the label and more than half of these substances contained
ingredients not disclosed on the label (Alostad et al., 2018). The fact that many herbal
medications currently on the market contain undocumented materials poses a significant
risk for consumers, especially if that ingredient can cause an allergic reaction or other
adverse side effects or if that material is of poor quality.
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The DSHEA along with all other FDA regulation policies allows manufacturers
and sellers to use fillers or substitutions in their products, which once again, constitutes
not only as food fraud but also poses health issues for consumers. Current analytical and
quantification techniques fail to identify all the active ingredients in most herbal
supplements, partly due to the combination of organic chemicals that many of these
products contain. Even with standard chemical practices used by all manufacturers for
analyzing the number of active ingredients in the supplement, there is still not enough
information to discern whether these active components exhibit an adverse side effect
(Newmaster, Grguric, Shanmughanandhan, Ramalingam, & Ragupathy, 2013). In
comparison to many other countries, who require herbal supplements to pass pre-market
approval, the current U.S. regulatory system, when it comes to herbal medicine, is
severely lacking. Rather than a preventative approach, the FDA allows unproven
supplements to enter the market and directly reach consumers.

The current regulation system puts consumers at risk because these policies
seemingly downplay the potential effects of herbal medications; rather, the regulation
should reflect the potential risk posed by consumption of these products. Currently, the
FDA encourages voluntary recall of the supplements they find adulterated or
contaminated. In 2018, the FDA issued its first mandatory recall for herbal products
containing kratom, an herb that has psychotropic effects, produced by the manufacturer
Triangle Pharmanaturals LLC (FDA, 2018). However, this only affects a small number of
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supplements on the market. Taking a preventative approach, these products should have
to undergo pre-market approval and at the very least, provide data that demonstrates its
safety in consumption. The burden of proof, therefore, shouldn’t lie with the FDA, but
manufacturers and sellers alike should play an active role in elucidating the efficacy,
safety, and quality of their products.

25

Chapter 3.1: The complexity of Pharmaceutical Drugs and Herbal Supplement Use
During Pregnancy
Pregnancy is marked by large changes to both the maternal physiology and
environmental changes. On top of navigating numerous prenatal visits, scans, and tests,
women must also rethink their medication regiment. The FDA has established a
categorical system to delineate the safety of different medications during pregnancy,
which can be summarized in

Table 1. This system allows healthcare providers to identify which medications to

recommend or prescribe, considering the associated side effects. Only a small number of
herbal supplements have been categorized using this system. The development of the
fetus and hormonal changes during all three trimesters of pregnancy alters the effect of
many different drugs. This complicates the trajectory of care. To better understand the
hazards of medications on both the development of the fetus and the maternal system, we
will first look at the multitude of hormonal changes that occurs during each trimester of
pregnancy. These fluctuations cause many of the symptoms experienced, and hence,
opens the door to treatment by pharmacological and/or herbal therapies. We will then
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compare the pharmacological therapies with the herbal remedies, looking specifically at
the mechanism of action, the side effects, and the potential interactions with other
substances.

Table 1: FDA pregnancy risk categories for different medications with examples of drugs that fall
into each category. Information obtained from Survey, J. & Chang, J. (2014). Over-the-counter
medications in pregnancy. American Family Physician, 90(8), 548-555.
https://doi.org/10.1016/j.acthis.2015.01.004

Category

Description

Examples

Category A Adequate and well-controlled studies
have failed to demonstrate a risk to the
fetus in all trimesters
Category B Animal reproduction studies have
failed to demonstrate a risk to the fetus
There are no well-controlled studies in
pregnant women
Category C Animal reproduction studies have
shown adverse effects on the fetus
There are no well-controlled studies in
humans
Potential benefits may warrant the use
of the drug during pregnancy
Category D There is evidence of human fetal risk
based on adverse reaction data from
studies in humans
Category X Studies in animals or humans have
demonstrated fetal abnormalities
The risks involved clearly outweigh
the potential benefits
27

Acetaminophen
Benadryl

Guaifenesin (Humibid L.A.)
Miconazole (Monistat)
Calcium Carbonate (Tums)

Aspirin (in the third trimester)
Ibuprofen (in the third
trimester)
Castor oil

Changes in Maternal Hormones and Metabolism
To successfully develop a zygote, a fertilized egg, into an infant requires complete
rewiring of maternal metabolism. Throughout the approximately 280 days of a normal
human pregnancy, changing biochemical parameters dictate a whole orchestra of
physiological changes to support a pregnancy. Steroid hormones, peptide hormones, and
prostaglandins help to establish a protective environment for fetal growth and develop a
system for the transportation of nutrients between maternal and fetal systems (Lockitch,
1997). Disruptions to the normal function of these interactions may cause serious side
effects in both the fetus and the mother. Thus, pregnancy presents an interesting dilemma
in terms of the use of medicines and alternative medicines. Side effects and the molecular
influence of both pharmaceutical drugs and herbal medications should be stringently
documented and researched to prevent adverse interactions and side effects.
The four main hormones that govern pregnancy are estrogen, progesterone,
human placental lactogen (hPL), and human chorionic gonadotropin hormone (hCG).
These hormones are synthesized by the placenta throughout most of the pregnancy and
28

rely on the metabolic relationship between the maternal and fetal systems. The patterns of
estrogen, progesterone, and hCG can be summarized in Figure 2. It should be noted that
estrogens, progesterone, and hLP follow a similar pattern with lower levels during the
beginning of the pregnancy before gradually increasing and peaking near term
(Blackburn, 2007).

Figure 2: Graph depicting patterns of estrogen, hCG, and progesterone levels during
pregnancy from fertilization to labor. Figure adapted from Guyton, A.C (1987). Human
Physiology and mechanisms of disease (4th ed.). Philadelphia: Saunders.
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In the weeks following conception, hCG levels can be detected in the blood in 7
days after ovulation, and substantially increases until concentrations in the maternal
serum peaks at around 8 and 12 weeks before slowly declining. The sudden rise in hCG
extends the functionality of the corpus luteum (CL), a structure that allows for the
production of progesterone, into a couple of weeks allowing the body to sustain the
pregnancy until the placenta takes over. Moreover, studies indicate that hCG may play a
role in the implantation of the embryo to the uterine wall. Receptors on the endometrium
(the uterine lining) promote the secretion of relaxin and progesterone by the CL, which
stimulates the physiological changes required in early pregnancy. Abnormalities in the
expression of hCG receptors and abnormal levels of the hormones itself can be associated
with issues in female reproduction and pregnancy (Keay et.al., 2004; Lockitch, 1997).
With hCG maintaining the functionality of the corpus luteum, levels of
progesterone, a steroid hormone in the maternal serum remains elevated. Under the
influence of hCG, progesterone is produced by the CL until its production is sustained by
the placenta 6-8 weeks after fertilization. Progesterone combats the labor-inducing effects
of other hormones such as estrogen, prostaglandins, and oxytocin, allowing for the
pregnancy to sustain. In addition to preventing menstruation, which would shed the
30

uterine lining needed for implantation of the ovum, progesterone, a pro-gestational
hormone, maintains pregnancy by promoting uterine quiescence. The myometrium, the
smooth muscle of the uterus, plays a large role in the duration of pregnancies and in the
birthing process. Through most of the pregnancy, the myometrium remains in a relaxed
state, stretching to accommodate the growing fetus mainly sustained by the presence of
progesterone. At the time of birth, rhythmic contractions of the myometrium allow for the
expulsion of the fetus and placenta. After 8 weeks of pregnancy, the main production of
progesterone shifts from the CL to the placenta and placental trophoblasts, where the
levels of progesterone remain elevated until the placenta is lost following parturition.
Interestingly, disruption in the production of progesterone initiates labor by stimulating
uterine contractions. Clinical studies indicate that progesterone supplement may decrease
preterm labor in women with high risk for preterm labor, however, more research is
needed before this treatment can be applied clinically (Mesiano et.al., 2011; Tuckey,
2005). Progesterone also serves as a substrate for the production of corticosteroids by the
fetal adrenal gland. Due to insufficient levels of enzymes required to form several
different corticosteroids, the fetus is unable to use the main metabolic pathway to form
these components. Thus, they rely on progesterone produced by the placenta using
precursors from the maternal system to form mineralocorticoids and corticosteroids,
which are hormones that hold physiological importance (Blackburn, 2007).
Estrogen exists within the body in three major forms: estrone, estradiol, and
estriol. During pregnancy, levels of all three major estrogens substantially increase.
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Notably, levels of estradiol production increase almost 1000 times baseline levels by the
third trimester of the pregnancy. Estrogen, like hCG and progesterone, is mainly
produced by the placenta, however, unlike progesterone, 90% of the precursors are
derived from the fetus instead of the maternal system. Furthermore, while progesterone
decreases myometrial activity and promotes myometrial constriction, estrogen provides
the opposite effect – enhancing myometrial activity and promoting myometrial
vasodilation. In addition to effects on the uterine wall, estrogen derivatives also increase
maternal sensitivity to carbon dioxide and secretion of other hormones such as prolactin
and serum binding proteins (Blackburn, 2007).
Another key component in developing the environment to sustain a pregnancy
revolves around changing maternal metabolism to support the development of fetal
metabolism, as task mediated by the hormone hPL. Almost exclusively secreted by the
placenta into the maternal circulation, hPL is hypothesized to be responsible for the rise
in maternal plasma insulin-like growth factor (IGF-1). During early pregnancy, hPL and
other placental hormones drive an increased appetite and food intake as well as energy
storage leading to an increase in the deposition of fat reserves. As the pregnancy
progresses towards term, hPL mobilizes these reserves to support fetal growth (Magon &
Kumar, 2012).
Use of Medicine During Pregnancy: An Upward Trend
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With a whole slew of changes occurring, pregnant women often experience a
whole array of different symptoms, ranging from emesis to constipation to fatigue.
Because of the complex physiological changes coupled with dynamic shifts in hormones
and metabolic homeostasis, the use of medication to address symptoms in pregnancy
proves to be difficult for providers to navigate. Providers must balance not only the
effects of these medications on the mother but also an unintended subject, the fetus.
Perhaps one of the biggest medical disasters revolves around the severe birth defects
affecting over 10,000 children globally from 1957 to 1962. At the center of this tragedy
lies Thalidomide, a drug prescribed to women to treat morning sickness. Administration
of this drug caused severe birth defects including limb development and significant organ
tissue damage in infants worldwide (Ghoreishi, 2014). The thalidomide crisis greatly
impacted the dynamic of medication use during pregnancy.
For the past several decades, the use of both over the counter medications as well
as prescription medicine during pregnancy shows a substantial increase. As depicted by
the figure below, in 2008, 93.9% of women reported taking at least one medication
anytime during the pregnancy, a substantial increase from around 50% in 1967-1981.
Moreover, this figure also supports the notion that the average number of medications
taken follows a similar upward trend, from an average of 2.5 drugs in 1976 to over 4 in
2008. The number of women taking four or more medications also increased, from 23.3%
in the late 1970s to 50.1% in 2008. Interestingly, this trend continues into the current day
(Mitchell et al., 2011). In a 2018 study, out of 9,546 women surveyed, 95.7% took
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medication during the first trimester with 30.5% meet the requirements for
polypharmacy, defined as taking five or more medications. Excluding vitamins and
herbal supplements, 74.4% of women took at least one medication during pregnancy
(Haas et al., 2018; Lee et al., 2006). \

Figure 3. Average medication uses during pregnancy and the first trimester. The chart
shows an upward trend in medication usage throughout the duration of pregnancy.
Figure adapted from Mitchell, A. A., Gilboa, S. M., Werler, M. M., Kelley, K. E., Louik,
C., & Hernandez-Diaz, S.. (2011). Medication use during pregnancy, with particular
focus on prescription drugs: 1976-2008. American journal of Obstetrics and Gynecology,
205(1), 51.e1-51.e8. http://doi.org/10.1016/j.ajog.2011.02.029.
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Drug safety thus remains a major priority for both researchers and providers.
Since the thalidomide crisis, many pharmaceutical drugs have been classified as
teratogens, a substance that can cause malformations in a developing embryo. Warfarin,
an anticoagulant medication, valproic acid, an anticonvulsant, and isotretinoin, an acne
medication serves as examples of teratogens. As a result, many of these pharmaceutical
drugs are strictly modulated and monitored by pharmacists and healthcare workers.
However, the regulation of over the counter medications (OTC) use poses a difficult task,
relying mostly on patient disclosure. While the prevalence of OTC and their easy
accessibility suggests usage safety by nonpregnancy populations, this doesn’t extend to
safety during pregnancy (Servey & Chang, 2014). Little to no data exists detailing the
long-term effects of most OTC medications. Thus, given their prevalence in routine
obstetric care, stringent research on the potential side effects and interactions should be
conducted to ensure the safety of both the mother and the fetus.
The upward trend in medication use during pregnancy also extends to herbal
supplement use during pregnancy. In fact, a vast range between 7% to 55% of expectant
mothers globally reported using herbal remedies or other types of natural health products
during pregnancy and lactation (Facchinetti et.al., 2015; Yusof et.al., 2016). Prevalence
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of usage is dependent on geography as well as demographics. According to various
studies, the top four herbal medicines used by pregnant women globally are ginger to
treat nausea, valerian to aid with insomnia, and raspberry to induce labor (Abebe, 2002;
Holst et.al., 2011; Kennedy et.al., 2013).

Table 2 provides a summary of several herbal supplements commonly used during

the first three trimesters of pregnancy with their intended benefits, the risks associated
with usage, and documented interactions with other medications. Like OTC medications,
the regulation of complementary and alternative medicine proves a difficult task. Without
a prescription requirement, these substances can be readily purchased at different stores
and sources without stringent quality control by the FDA. Moreover, often, women
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neglect to inform their midwife or physician about herbal medicine use, increasing the
chances of herb-drug interactions during pregnancy (Hall et.al., 2011; Kennedy et al.,
2013).

Table 2: Common herbal supplements used by women during pregnancy.1 (Abebe, 2002), (Tiran,
2012); 2 (Holst et al., 2011); 3 (Abebe, 2002) 4 (Holst, Haavik, & Nordeng, 2009); 5 (Dugoua,
2010), (Dugoua, Seely, Perri, Mills, & Koren, 2008); 6 (Dugoua, Jean-Jacques; Mills, Edward;
Perri, Daniel; Koren, 2006); 7 (Newmaster et al., 2013)

Herbal
Supplement
Ginger 1

Reason for use

Benefits

Associated risks

Interactions

To treat
morning
sickness, cold
and flu-like
symptoms,

Diaphoretic
properties

Stomach irritant,
Heartburn

Anticoagulant
effects that
might interfere
with
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gastrointestinal
diseases

No reported
increase in birth
malformities

Cranberry 2

To treat UTIs,
colds, water
retention

Research
shows
questionable
efficacy in
preventing
recurrent UTI
in pregnancy

No significant
side-effects
reported

Valerian 3

To treat
insomnia and
restlessness

Induce mild
sedation and
hypnosis

No reported risk
to the fetus
Valerian
withdrawal
mimics
withdrawal of
ben
Benzodiazepines

Raspberry Leaf 4

Flu and cold
symptoms, to
prime the uterus
for labor,
stimulate labor

Research
shows
contradictory
results for the
efficacy; the
active
component
remains
unidentified

None
documented
No evidence of
fetal malformities

Blue Cohosh 5

To prepare for
labor

Evidence of
initiating

Several cases of
in vivo evidence
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anticoagulant
drugs

Can potentiate
the sedative
effects of other
central
nervous
system drugs

Ginkgo 6

Senna7

To use for
premenstrual
syndrome
(PMS)

To treat
constipation

uterine
contractions

of teratogenic,
embryotoxic, and
oxytocic effects

Strong
evidence for
therapeutic use
for
intermittent
claudication,
dementia,
altitude
sickness, and
vertigo

The antiplatelet
activity could
prolong bleeding
during delivery

Evidence of
laxative
effects

Prolonged use
can cause chronic
diarrhea, liver
damage,
abdominal pain

May potentiate
anti-clotting
effects of
anticoagulant
medications

No risk
associated with
consumption
during lactation

(Sennosides)
Interact with
immune cells
in the colon

Dangers of Medication Use During Pregnancy
As mentioned, drug use during pregnancy poses an imminent challenge to the
current healthcare system. A portion of this issue is attributed to holes in clinical practice
and FDA regulation, but another compounding factor comes from the changes in
maternal drug metabolism. Expanding on the hormonal changes, pregnancy is also
hallmarked by distinct physiological changes including a significant increase in a plasma
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volume expansion of erythrocyte mass, altered distribution of cardiac output, and an
increase in plasma protein synthesis (Lockitch, 1997).

Table 3 shows changes in absorption, distribution, metabolism, and excretion that occurs
during pregnancy. Alterations in the maternal system change the way drugs and
supplements are metabolized, thus changing the effect and potency of many drugs. For
example, an increase in renal blood flow and pulmonary function during pregnancy may
decrease the effectiveness of medications, due to the increase in excretion efficiency. Due
to large metabolic changes and hormonal changes, prescribing drugs during pregnancy
remains a difficult task for healthcare providers. They must consider a multitude of
changes and factors to ensure the safety for the mother as well as the fetus while also
treating various symptoms that arise during pregnancy.

Table 3: Changes to factors that influence metabolism of drugs during pregnancy.
Adapted from Reed, MD * Blumer, J.L. (2006). Pharmacologic treatment of the fetus. In
R.J. Martin, A.A. Fanaroff & M.C. Walsh (Eds.). Fanaroff and Martin’sneonatalperinatal medicine: Diseases of the fetus and infant (8th ed.), Philadelphia: Saunders
Influence of Pregnancy on Physiological Aspects of Drug Disposition
Pharmacokinetic Parameter
Change in Pregnancy
Absorption
Gastric emptying
Increased
Intestinal Motility
Decreased
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Cardiac Output

Increased

Distribution
Plasma Volume
Total body water
Plasma proteins
Body fat

Increased
Increased
Decreased
Increased

Metabolism
Hepatic
Extrahepatic
Plasma proteins

Increased or Decreased
Increased or Decreased
Decreased

Excretion
Renal blood flow
Pulmonary function

Increased
Increased

.

Chapter 3.2: Treating Symptoms During Pregnancy: A Look at Common
Pharmacological and Herbal Options
Morning Sickness: An Imbalance of hCG
Nausea and vomiting or emesis are some of the most common symptoms
experienced by expectant mothers with nausea affecting 75% of pregnant women and
emesis occurring in 50% of pregnant women. In a small number of patients, hyperemesis
gravidarum, a condition characterized by persistent vomiting leading to dehydration and
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weight loss, may develop. Typically manifesting in the early weeks of the first trimester
and peaking at around 9 weeks of gestation, most instances resolve by the end of the first
trimester. The severity of nausea and vomiting of pregnancy (NVP) can range from mild
to unbearable instances, lasting throughout the day, contrary to the public term of
morning sickness (M.L., S.M., & J.A., 2006; Niebyl, 2010). Interestingly, the clinical
course for NVP correlates with the levels of hCG. In theory, an increase in hCG,
especially during pregnancy, may stimulate the production of estrogen, a hormone known
to increase instances of nausea and emesis (Niebyl, 2010). The vomiting center, when
activated, mobilizes motor neurons that descend down the cranial nerves to the upper
gastrointestinal tract before reaching the vagal nerve, a cranial nerve controlling the
digestive tract. The activation of this center causes the contraction of the abdominal
muscles and the diagram, initiating the action of vomiting. Irritants are known to activate
this center. In addition, the presence of certain hormones and neurotransmitters might
trigger this center (Becker, D.E., 2010).
An Overview of Treatments for NVP
Clinically, multiple methods can be used to alleviate NVP and improve the
quality of life for expectant mothers. Broken into two general groups, providers may
employ a pharmacological approach or a nonpharmacological approach, each treatment
containing a different set of benefits and disadvantages. The first approach to NVP
treatment generally involves behavioral and environmental changes. While the efficacy
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of this approach remains unproven, women are often encouraged to shift their diet –
consuming smaller meals and avoid spicy foods. In addition, providers might encourage
women to take their prenatal vitamins at night and suspend iron therapy (M.L. et al.,
2006).
The use of herbal medicine also falls within the category of nonpharmacological
approaches. The most common herbal supplement used to treat nausea is ginger (Zingiber
officinale). Widely used as a spice to enhance the flavor of food, ginger is among the top
20 selling herbal supplement in the United States. Various preparations of ginger exist,
including extract in teas, capsules, or root powder. Due to a lack in federal oversight, the
dosages present in these different preparations and brands may vary greatly – from 250
mg to 1000 mg (Borrelli et.al., 2005; Ebrahimi et.al., 2010). While the mechanism
employed by ginger has not been fully elucidated, the antiemetic effects are attributed to
gingerol. Other components such as galanolactone are thought to act as serotonin and
vasopressin antagonists to decrease tachygastric activity especially in the ileum, a portion
of the small intestine. Interestingly, some prescription anti-emetics employ the same
mechanism (Tiran, 2012). Multiple studies indicate that ginger is effective in reducing the
severity of NVP (Borrelli et al., 2005; M.L. et al., 2006; Ozgoli et.al., 2009; Westfall,
2004).
If symptoms persist or worsen, providers turn towards pharmacological therapies.
A number of different drug categories can be considered to manage nausea and vomiting
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during pregnancy. Antihistamines, such as meclizine and diphenhydramine (Benadryl ®),
directly inhibit the action of a histamine receptor, thus indirectly decreasing the
stimulation of the vomiting region. The effectiveness of antihistamines has been proven
over a series of tests conducted in the 1960s. Another class of drugs typically used to
treat NVP is dopamine antagonists (Metoclopramide), serotonin antagonists
(Ondansetron), and cholinergic antagonists (dicyclomine and scopolamine). These
antagonists block certain receptors in the vomiting center or certain digestive sites to
decrease stimulation or triggers that might activate these areas (Becker, D.E., 2010).
Risks/Interactions Associated with Nonpharmacological Methods
Despite limited research, many clinical studies indicate that ginger proves to be
an effective and safe method to manage NVP. However, limited data exists on the
appropriate dosage of ginger to achieve optimal results. One study indicates that a daily
dose of 1000 mg, in the form of a capsule achieves a reduction in the intensity of nausea
and vomiting in women (Ozgoli et al., 2009). Generally, a dosage of 1000 mg or less per
day is deemed safe. Multiple randomized controlled trial studies show a reduction in
symptoms with infrequent side effects overall (Ebrahimi et al., 2010). There is still a lack
of studies detailing the effects of extended use of these supplements on the mother and
the fetus. Moreover, as mentioned before, due to a lack of FDA regulation, each
preparation of ginger may contain different amounts of active ingredients, thereby
altering the effectiveness of the treatment. Additionally, minimal federal oversight into
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the quality and manufacturing of herbal medicines, including ginger, leaves the door open
of adulterations.
The use of ginger may result in a multitude of symptoms, many due to
interactions with other medications. Recently, several studies indicate that ginger
contains anticoagulant effects. When taken in tandem with other anticoagulant therapies
such as Warfarin or aspirin, the effects of these drugs can substantially increase. Thus,
women with a past medical history of vaginal bleeding or clotting disorders are
encouraged to avoid taking ginger during their pregnancy. In addition to interactions with
anticoagulants, ginger also shows potential to interact with other classes of drugs such as
benzodiazepines, beta blockers, barbiturates, and other herbal medications (Tiran, 2003).
As one of the most popular and studied herbal supplement, the use of ginger in
primary care and in pregnancy seems to be a safe and inexpensive option. However,
despite promising research, the lack of regulation in purity coupled with lenient dosage
management by the FDA should raise concerns. Ginger can exacerbate the effects of
anticoagulants and interact with other drugs. Due to the tendency of patients to exclude
the use of herbal supplements from healthcare providers, the risk of herb-drug
interactions substantially increases. While generally safe to use during pregnancy,
caretakers should monitor ginger and other herbal supplements similar to the way to
manage pharmaceutical drugs.
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Risks/Interactions Associated with Pharmacological Methods
Compared to their herbal medicine counterparts, the pharmacological methods are
better researched in terms of their exact mechanism, teratogenic effects, and safety.
Multiple studies on the safety and effectiveness of dopamine, serotonin, and cholinergic
antagonists indicate almost no teratogenic effects or adverse side effects for the mothers
(Ebrahimi et al., 2010; M.L. et al., 2006; Niebyl, 2010).
Biochemical Changes Associated with Sleep Disturbances in Pregnancy
Another common symptom reported by 66% to 94% of pregnant women reports
sleep disturbances, including insomnia. Due to marked mechanical changes coupled with
hormonal fluctuations, the quality and length of sleep change profoundly. Ailments such
as lower back pain, leg pain, and abdominal discomfort affect the architecture of sleep.
Pregnant women tend to have increased light sleep (stage 1 sleep) and suppression of
REM or deep sleep. Importantly, as seen in

Figure 4, the marked elevation of progesterone and estrogen due to pregnancy plays a

large role in changing the quality of sleep. Estrogen decreases REM sleep as well as
increase upper airway resistance by causing swelling. The increased difficulty breathing
might play a role in sleep disruption. Progesterone, on the other hand, increases nonREM sleep. Similar to the effect of estrogen on the airway, progesterone increases
ventilation and respiratory alkalosis, leading to instability in the airways and disruption in
sleep. Furthermore, because progesterone shares binding sites on corticosteroid binding
globulin, an increase in progesterone level directly correlates to an increase in free
cortisol. This disturbance in the cortisol-melatonin ratio is hypothesized as a cause of
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sleep disturbances and insomnia (Kizilirmak et. al., 2012; Reichner, 2015; Sharma et. al.,
2004).
Interestingly, the typical sleeping pattern of expectant mothers’ changes and shifts
throughout the trimesters. During the first trimester, the rise in progesterone may cause
daytime sleepiness. However, even though there is a meaningful increase in sleep
duration, the efficiency and quality of sleep remain depressed, thus, common complaints
during this period may also include fatigue. In the second and third trimesters, the total
night-time sleep duration falls, resulting in an increase in non-REM sleep and a reduction
of REM sleep. Nocturnal disturbances become increasingly common. Some women can
develop insomnia or difficulty falling asleep (AM, SK, SK, & IS, 2016; Pien & Schwab,
2004; Sharma et al., 2004).
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Figure 4: Impact of different hormones on the quality of sleep in pregnancy. Figure adapted

from Guyton, A.C (1987). Human Physiology and mechanisms of disease (4th ed.).
Philadelphia: Saunders.
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Overview of Treatments for Insomnia During Pregnancy
Similar to the treatment for NVP, sleep disruptions can be mediated by
nonpharmacological methods and pharmacological therapies. Nonpharmacologic
interventions include sleep hygiene and sleep education as well as behavioral therapy.
Changing the surrounding environmental factors by avoiding certain foods, dimming the
lights, and changing sleeping position may help promote a restful night of sleep. A step
above sleep hygiene and education involves behavioral therapies that promote relaxation,
employ sleep restriction, and decrease anxiety and stimulus through cognitive therapy
(AM et al., 2016). Another major alternative or nonpharmacological therapy utilizes
herbal supplements to promote sleep. Valerian (Valeriana officinalis) is an herb
commonly recognized for its sedative effect often available in many different
preparations including extracts, infusions, and tinctures. With a mixture of active
ingredients, the main mechanism of valerian is attributed to valerenic acid and
sesquiterpenes. By inhibiting the breakdown of the enzyme charged with the degradation
of GABA, valerian causes a decrease in activity in the central nervous system resulting in
a sedative effect (Abebe, 2002; Houghton, 1998).
If insomnia persists, a limited number of pharmacological therapies may be
considered for short-term use. Most sedative-hypnotics remains unsafe for use during
pregnancy, however, diphenhydramine (Benadryl) or zolpidem (Ambien) when used
infrequently are currently considered safe for the mother and the fetus. Similar to the
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proposed mechanism for valerian, zolpidem acts on GABA receptors to induce sedation
(Doble, 1996). The medical community still remains divided on the use of Zolpidem
during pregnancy due to uncertainty about dosage and potential side effects.
Diphenhydramine, a known histamine receptor antagonist, induces sedation by altering
the regulation of the sleep-wakefulness continuum (Turner, Handford, & Nicholson,
2006). Insomnia remains a difficult disorder to treat, and stringent drug management is
imperative in preventing adverse side effects.
Risks/interactions Associated with Nonpharmacological Therapies
Only a handful of clinical trials and experiments have been conducted on the
effectiveness and safety of valerian. Both clinical and animal studies can have sleepinducing and tranquilizing effects in-vivo. With a mixture of different constituents,
valerian utilizes several different mechanisms to cause a tranquilizing or sedative effect.
However, the activity of valerian is dependent on the concentration of its constituents.
Due to a variety of different preparations, the effectiveness of this herbal supplement
greatly varies from company to company. With current FDA regulations, no formal
standardization for the preparation of valerian currently exists, which raises concerns
about safety.
Limited research exists studying the pharmacokinetic and pharmacodynamic
interactions between valerian and other herbal medications or pharmaceutical drugs. Due
to its effect on GABA, interactions with barbiturates and opioids are plausible. Valerian
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may exert an additive or antagonistic effect in response to tranquilizers, other sedative
medications, and opioids. In addition, some studies indicate that valerian potentially
reduces the effect of antidepressants when taken in tandem. In vitro evidence also
suggests that valerian might inhibit CYP, opening the door for potential interactions with
CYP substrates such as warfarin and atorvastatin. (Abebe, 2002; Cramer et.al., 2006;
Houghton, 1998).
Risks/Interactions Associated with Pharmacological Therapies
In general, pharmacological treatments for insomnia and sleep difficulty during
pregnancy should be short-term. Most sedatives may be teratogenic, posing a significant
risk towards the fetus. Currently, no official pharmacological therapy for insomnia is
classified as safe during pregnancy. Zolpidem has been shown to increase symptoms of
depression when combined with central nervous system acting drugs such as Tramadol
and Alprazolam. This indicates that Zolpidem might influence the metabolism and hence
the function of other medications. Due to its interactions with GABA receptors in the
brain, potent interactions between Zolpidem and illicit drugs that interact with the central
nervous system may cause catastrophic side effects. Other categories of sedative
pharmaceutical therapies also pose a major risk to the fetus, such as drug withdrawal
symptoms following birth (Jazbar et. al., 2018).
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Chapter 3.3: Induction of Labor: A Review of Pharmacological and Herbal
Methods
Induction of Labor: Biochemical changes
The initiation and development of a pregnancy, as discussed earlier, relies on a
whole orchestra of hormones and molecules. Similarly, the initiation and stimulation of
labor are greatly dependent on several major proteins: progesterone, prostaglandins,
interleukin-8, and oxytocin receptors. As mentioned above, progesterone levels remain
high during pregnancy to combat labor-inducing effects. This steroid hormone inhibits
the ripening of the cervix, governed by another hormone, as well as combat the effects of
labor promoting hormones. While there is no noticeable progesterone withdrawal during
human pregnancy, some studies indicate that progesterone might undergo a “functional”
withdrawal. Speculation into the role of progesterone during labor remains debated and
postulated. Another important hormone in inducing labor is prostaglandins, which
stimulate myometrial contractility and cervix ripening. Changes in the synthesis and the
metabolism of prostaglandins fluxes over the duration of the pregnancy and plays a role
in governing the labor process. Up-regulation of prostaglandins near the end of
pregnancy stimulates contractions during labor. The hormone interleukin-8 is produced
by the endometrium, myometrium, decidual cells, and the placenta. The expression of
this hormone correlates with increasing gestational age, suggesting that interleukin-8
might play a role in ripening the cervix prior to cervical dilation. The final key player in
the induction of labor in humans is the oxytocin receptors. Increased sensitivity to
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oxytocin in the myometrium plays a large role in promoting uterine contractions, thus,
biochemical changes both the levels of oxytocin and the affinity of oxytocin receptors to
their substrate largely contributes to the induction of labor (Mohan et. al., 2004). Figure 4
shows a summary of the regulators involved in labor induction. This figure also shows
that other secondary factors such as nitric oxide and ion channels, while not discussed
thoroughly in this paper, also plays a major role in the induction and sustaining labor.
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Figure 5: The relationship of major hormones and regulators in relation to uterine
contractility and parturition. CRH, corticotropin-releasing hormone; NO, nitric oxide;
PGI2, prostacyclin, PTHrP, parathyroid hormone-related peptide. Adapted from Challis,
J.R.G. (1999). Characteristics of parturition. In R.K. Creasy & R. Resnik (eds.).
Maternal-fetal medicine (4th ed.). Philadelphia, Saunders.
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An Overview of Methods for Labor Induction
The labor process, both in duration and onset, greatly varies across individuals.
Preterm labor, classified as parturition prior to 37 weeks of gestation, may cause fetal
distress. Similarly, post-term labor, classified as parturition after 40 weeks, poses a risk to
fetal wellbeing due to insufficient nutrition derived from the placenta. In cases of fetal
distress, maternal distress, or postdate pregnancy, providers often employ a range of
different methods to induce labor. The first step in labor induction revolves around
ripening the cervix. Promoting the cervix to absorb water and become more malleable
increases the chances for successful vaginal delivery. Mechanical approaches such as
inserting a balloon catheter to apply direct pressure on the cervix may be used to ripen the
cervix (Tenore, 2003). The primary pharmacological method for induction of labor
involves cervical ripening by misoprostol (Cytotec) and promotion of uterine contraction
via Pitocin, a synthetic version of oxytocin. Alternative methods, particularly herbal
methods indicated in inducing labor includes blue cohosh, raspberry leaf, evening
primrose, and castor oil. Comparing the mechanism and the possible interactions of both
the pharmacological method and alternative methods elucidates on the importance of
using scientifically backed methods to ensure the safety of the expectant mother and the
baby.
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Herbal Supplements as Labor Inducers
Many different herbal medications and preparations have been used by women to
aid or induce labor. Of these, blue cohosh, red raspberry leaf, castor oil, and evening
primrose make up the most common herbal supplements used for cervical ripening,
induction, and augmentation of labor. The mechanism for both evening primrose and
raspberry leaf remains relatively unknown. Little to no clinical research exists to help
elucidate both the safety and efficacy of these two herbal medications. Only a handful
clinical studies suggest that raspberry is a safe and effective method to induce labor,
however, many of these trials are small with no statistically significant data (Hall et.al.,
2012). Caretakers still debate over the efficacy and safety of both evening primrose and
red raspberry leaf. Due to a lack of research, pregnant women are often discouraged from
taking these supplements.
Castor oil (Oleum Palmae Christi) is an ancient herbal medication derived from
the seeds of Ricinus communis. Historically used to promote bowel movements and to
treat inflammation, Castor oil has also been documented as a labor inducer in women at
term. Ricinoleic acid, a hydroxylated unsaturated fatty acid, constitutes the main
pharmacological mechanism of castor oil. Ricinoleic acid is a selective agonist of EP3, a
prostaglandin receptor presents in both the small intestine and the myometrium.
Consumption of castor oil and subsequently ricinoleic acid activates EP3 receptors on
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smooth muscle cells in the uterus, thus initiating symptoms associated with labor (Tunaru
et. al., 2012).
Blue Cohosh (Caulophyllum thalictroides) is derived from a perennial plant with
large blueberries. In the late 1990s, up to 64% of practicing midwives prescribed Blue
Cohosh to induce labor and help speed up the process of delivery. However, several case
reports suggest that Blue Cohosh may be associated with myocardial infarction, hypoxic
injury, and cardiovascular birth defects (Dugoua et.al., 2008; Xia et al., 2014). The
preparation of Blue Cohosh yields several important active constituents such as alkaloids
and triterpene saponins. While these components show biological activity in antiinflammatory and analgesic effects, the exact mechanism for the induction of labor
remains unknown (Xia et al., 2014). Blue Cohosh was shown to enhance estradiol
binding to its receptors to increase the effect of estrogen, which may help initiate the birth
process (Mills et.al., 2006).
Interestingly, Cytotec shares a similar mechanism with castor oil, yet they wildly
differ in terms of their regulation and standards. Both either directly or indirectly
influences the expression and activity of prostaglandin, changing the motility of the
uterus. Generally, castor oil and other herbal preparations remain grossly under-regulated
by the FDA despite their pharmacologically active mechanisms. Comparison of Cytotec
and other herbal alternatives yields somewhat of a paradox. Despite patchy empirical
data, the FDA remains essentially quiet on herbal supplement regulations – adopting little
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regulation requirements and quality standards. Conversely, despite ample clinical data
suggesting the efficacy and safety of Cytotec as a labor inducer, the FDA has yet to
officially approve the use to this drug for that indication. Despite consumer perception,
both pharmacological and alternative methods operate under similar mechanisms, and
thus, should be held to the same standards.
Interactions Associated with Non-pharmacological Approaches
As with the case of herbal supplement raspberry leaf and evening primrose,
because the main active constituents and pharmacological mechanism remain unknown,
the potential for interactions with other compounds also remains unknown (Holst et.al.,
2009). Recently, studies on Blue Cohosh shows a whole slew of interactions and adverse
side effects. Studies indicate that Blue Cohosh might constrict coronary arteries and a
decrease in oxygen flow to the heart, thus, interacting with cardiovascular drugs such as
nitroglycerin, that cause vasodilation (Mills et al., 2006). These symptoms and
interactions remain relatively unexplored by researchers. In some ways, the increased
potential for interactions with other medications and alternative methods makes these
herbal medications more dangerous compared to other preparations and pharmacological
drugs. Without even a foundation of knowledge about functionality, taking these herbal
supplements in tandem with other drugs increases the change for severe interactions.
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Misoprostol (Cytotec): A Pharmacological Drug to Induce Labor
As mentioned above, prostaglandins are a group of compounds that have a major
effect on the labor process among other physiological processes. Misoprostol is a
synthetic analog that induces many of the same effects. Cervical ripening can be induced
by administering misoprostol orally or intravaginally. Prostaglandin administration
induces collagenase activation, which breaks down collagen in the cervix causing the
amount of collagen to be dispersed, resulting in a softer cervix. Application of
misoprostol also induces extracellular matrix remodeling and promotes uterine
contractions by sensitizing the myometrium to oxytocin. The use of this drug has been
linked to uterine tachysystole or excessive uterine contractions and changes in fetal heart
rate. Thus, proper monitoring of both maternal and fetal wellbeing remains an important
part of labor management. Interestingly, misoprostol in the U.S. is only approved by the
FDA for ulcer treatment. For the past 30 years, this drug has been used off label for labor
induction and cervical ripening, and despite years of empirical data supporting the use of
misoprostol in this role, no current FDA approval for this obstetrical indication exist. The
American College of Obstetricians and Gynecologists (ACOG) endorses the use of
misoprostol for induction, citing a large body of clinical evidence for its safety and
efficacy (Stephenson & Wing, 2015). Pitocin, a synthetic form of oxytocin, may be
titrated after cervical ripening to induce uterine contractions by increasing the
intracellular concentration of calcium. Both Cytotec and Pitocin dosage needs to be
stringently regulated to prevent polysystole and fetal tachycardia (Arias, 2000).
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Interactions Associated with Pharmacological Approaches
The conversion of Misoprostol into its pharmacologically active constituents
occurs in the stomach, thus the intake of food may alter its bioavailability. Thus, dosage
of Misoprostol should be altered to account for its variable metabolism. Despite studies
evaluating interactions between Misoprostol and NSAIDs (aspirin or ibuprofen) and other
classes of drugs, no clinically significant or relevant interactions were reported. The use
of misoprostol or Cytotec has no known drug interactions. Moreover, this
pharmacological therapy does not interact with the CY P450 enzymatic system often
indicated in drug metabolism and absorption (Davies et.al., 2001; Goldberg et.al., 2001).
The Gap Between Pharmacological drugs and Herbal Supplements
In this chapter, many different herbal supplements were examined for both safety
and efficacy with variable and inconsistent results. Ginger, one of the most studied herbal
supplements, yields promising results for usage during pregnancy. However, many of the
other herbal supplements such as valerian root and blue cohosh yielded little data and
potentially detrimental effects on both maternal and fetal systems. In comparison, the
pharmacological counterparts provided providers and patients with extensive research on
potential side effects for usage during pregnancy as well as efficacy. Despite containing a
whole mixture of pharmacologically active ingredients, herbal supplements remain
largely underregulated.
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A clear discrepancy in knowledge for the mechanism of action directly stems
from the difference in FDA regulation between pharmacological therapies and herbal
remedies. While drugs are required to pass premarket benchmarks, herbal supplements
adhere to no standardization or premarket regulations or tests. However, this is almost
like a double edge sword. Stringent testing on safety and efficacy aims to protect patients
from adverse side effects, public misconceptions on data and research may deter progress
in treatment.
The litigation and history of Bendectin, now marketed as Diclegis serves as a prime
example of how proper scientific and clinical research corresponds with public
misconceptions. After obtaining FDA approval in the 1950s, the doxylamine-pyridoxine
combination became widely prescribed. At the peak of use, almost 25% of women
reported taking this drug to manage NVP. However, coinciding with the Thalidomide
tragedy, the safety of Bendectin came under scrutiny by a skeptical public in the late
1960s and into the 1970s. Eventually, a slew of lawsuits came in claiming that Bendectin
as a teratogen, causing multitudes of birth defects in infants across the country. The
pharmaceutical company elected to remove Bendectin from the market, based on weak
claims unbacked by scientific studies. Shortly after, independent studies dispelled the
claims that the doxylamine-pyridoxine caused fetal deformities, affirming the
effectiveness and safety of Bendectin. However, this combination was only recently
introduced back into the pharmaceutical market. A 30-year gap between the removal and
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reintroduction of this highly effective drug left obstetric care with no FDA approved
medication to mediate NVP (Slaughter et. al., 2014).
Between the case studies with herbal supplements and pharmacological drugs,
clearly, there is an inconsistency in the effectiveness of FDA regulation. On one hand,
most herbal supplements remain largely underregulated and hence understudied. With
increasing popularity and usage, this potentially leads to different drug-herb interactions
and adverse side effects. On the other hand, stringent regulations on pharmacological
drugs limit the ability for the development of new techniques. Another major component
in regulation involved the public’s perception and understanding of the mechanisms and
effects of both pharmacological therapies and herbal therapies alike. Perhaps the notion
that herbal supplements are natural deters patients from investigating their mechanism
and side effects while pharmacological drugs are often viewed as unnatural and
associated with teratogenic effects. These preconceptions change the way the general
public interprets the data and regulations set by the FDA. An effective regulatory system
for both herbal supplements and pharmacological therapies should involve premarket
approval, disclosure of all physiological effects, and standardization while considering
the perspective of the general population.
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Chapter 4.1: The Complexity of Postpartum: Pharmacological and Herbal
Therapies in Treating Postpartum Depression (PPD)
Hormonal Changes Associated with PPD
In the days and weeks following childbirth, a woman’s body undergoes
significant physiological changes. Due to a dramatic decrease in weight, changes in social
and family dynamics, and hormone fluxes, women typically experience a wide range of
emotions, which can include a persistent depressive mood. One of the most expensive
diseases to treat in America is depression, with over 14.8 million adults suffering from at
least one major depressive episode in any given year (DBSA, 2016). PPD exists as a
subset of depression affecting women anytime within the first four weeks of the
postartum period to 8 weeks postpartum, affecting anywhere from 7% to 20% of all
women who gave birth (Schiller, Meltzer-Brody, & Rubinow, 2015). Some of the most
common symptoms of PPD include a persistent depressed mood, a decrease in interest of
leisure activities, and disturbances in appetite or sleep (Solomon & Bauer, 2018).
Research shows that the development of PPD is multifactorial, relying on a combination
of social and biological factors (McCoy, Beal, Miller Shipman, Payton, & Watson, 2006).
After giving birth, a woman’s body undergoes drastic biochemical changes in the form of
gonadal hormones, thyroid hormones, and pituitary hormones fluxes, causing a whole
array of varying symptoms. Changes in these the biochemical processes combined with
environmental stressors such as lack of support or marital conflict may lead to the
development of PPD.
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With such a high prevalence and increasing occurrence of PPD in routine OB/Gyn
care, PPD is a major health concern affecting the patient and their immediate social
groups. PDD, like major depressive disorder, can be treated using a combination of
intervention by medical personnel and medication. Understanding the biochemical
changes will help us elucidate out how herbal supplements and pharmaceuticals can
influence the signaling pathways.
Gonadal Hormones Changes
Hormones such as estrogen, progesterone, follicle stimulating hormone (FSH),
and luteinizing hormone (LH) play a large role in maintaining homeostasis and
reproductive function. On a more general level, these hormones also play a large role in
the regulation of emotion, arousal, and motivation. During pregnancy, estrogen and
progesterone levels are elevated, largely because of placental production and
contribution.
Estrogen exists as two main biologically active compounds: estradiol and estriol,
which increase in pregnancy from basal levels by 100-fold and 1,000-fold respectively.
However, estrogen levels crash after birth, returning to preconception levels by day five
of postpartum (Hendrick, Altshuler, & Suri, 1998). This sudden change in levels
correlates to the development of PPD and its associated symptoms both directly and
indirectly. Because of its role in controlling emotion, the sudden decrease in estrogen
correlates to the development of a persistent depressed mood that is also influenced by

64

psychological and social risk factors. Estradiol (E2), an active form of the hormone
estrogen plays an interesting role in the regulation of different biological systems and
pathways in the body. The presence of estradiol directly correlates with the function of
the serotonin, a potent neurotransmitter implicated in the regulation of euphoria. E2
increases the production of tryptophan hydroxylase, an important enzyme in catalyzing
the formation of serotonin from tryptophan. During the sharp decline in estrogen levels,
the levels of serotonin also decrease. In addition, E2 inhibits the expression for the gene
responsible for the reuptake of serotonin, allowing the neurotransmitter to increase its
activity in the synapses. The decrease in the E2 levels after birth increases the reuptake of
serotonin immediately after birth. Reuptake decreases the activity of these
neurotransmitters, leading to both mental and physiological symptoms such as fatigue
and a decrease in enjoyment of activities (McCoy et al., 2006; Rybaczyk et al., 2005).
Progesterone, another prominent gonadal hormone implicated in reproductive
function, also experiences significant fluctuations throughout the pregnancy and the
postpartum period. Following successful implantation of the zygote in the uterus, the
levels of progesterone remain high throughout the duration of the pregnancy both through
maternal and fetal contributions. This steroid hormone suppresses the maternal immune
system against fetal antigens and maintains the proper environment during embryodevelopment. On a more global scale, progesterone increases the activity of GABA
receptors, which are ion channels that govern the flow of ions into the cell. Increased
activity of GABA receptors decreases the excitation of the neuron, which can help
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decrease and modulate feelings of anxiety or fear. After the delivery of the placenta, the
levels of progesterone sharply decline during the postpartum period. Progesterone
withdrawal during the postpartum period can contribute to the anxiety symptoms seen in
PPD (McCoy et al., 2006; Tuckey, 2005).
Thyroid Hormones Changes
Interestingly, studies indicate that in the 6 months following delivery, new
mothers experience a higher incidence rate of thyroid dysfunction at around 7%
compared to the general population, whose incidence rate lies at around 3% to 4%
(Hendrick et al., 1998). The thyroid secretes differing levels of thyroid hormones to
regulate metabolism, temperature, heart rate, and the production of energy in the form of
ATP (Gnocchi, Steffensen, Bruscalupi, & Parini, 2016). Scientists hypothesize that
abnormalities in thyroid hormone concentration may serve as an indicator for the
development of major depression as thyroid dysfunction is often accompanied by
depression (Schiller et al., 2015). While the development of PPD isn’t directly correlated
with the presence of thyroid hormone abnormalities in most women, it appears to be a
significant factor for a certain subset of mothers (Hendrick et al., 1998).
Changes in thyroid hormones during pregnancy and levels of estrogen interacts
via biochemical flux. During pregnancy, as mentioned before, the levels of estrogen
remain elevated due to fetal contributions. This substantial gonadal hormone increase
also causes an elevation in the levels of thyroxine-binding globulin (TBG) and
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consequently, leading to a surge in circulating T4 levels, which is the inactive form of the
TH (Schiller et al., 2015). In addition, a placental contribution in producing excess
thyroid stimulating factors and an overall iodine deficiency may also contribute to a net
increase in T3/T4. In the case of diminished thyroid function, often referred to as
hypothyroidism, studies indicate a decrease in the amount of serotonin activity (Engelsen,
Fern, Ireland, Harris, & Silver, 2015; Hendrick et al., 1998).
Pituitary Hormones Changes
During the pregnancy and the birthing process, the increased levels of stress cause
a substantial elevation in levels of corticotropin-releasing hormone (CRH) and
adrenocorticotropic hormone (ACTH), leading to hyperactivation of the HPA axis. The
HPA axis or the hypothalamus-pituitary-adrenal axis is one of the major endocrine
pathways that influence our stress hormones. Activation of this pathway leads to a
response in by the sympathetic nervous system, activating our fight or flight response by
increasing the amount of cortisol released. The levels of cortisol, a hormone involved in
activating the stress response in the body, sees a significant drop approximately our days
after delivery. Yet, the HPA axis takes approximately 12 weeks postpartum to return to
normal function. This dysfunction in the regulation of cortisol may link hormonal
imbalance immediately following birth to the development of PPD (Schiller et al., 2015).
The stress hormone fluctuation is hypothesized to contribute to clinical symptoms
observed in PPD.
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Treatment of PPD: An Overview of Common Pharmacological Drugs and Herbal
Supplements
PPD and depression, in general, can usually be treated using a combination of
psychotherapy and medications, such as selective serotonin reuptake inhibitor (SSRI).
These drugs work by decreasing the activity of molecules that remove serotonin, which is
a neurotransmitter linked to the feelings of euphoria, from the area between a synapse.
This allows for a prolonged increase in the levels of serotonin in the brain, which can
help increase its activity and alleviate symptoms typically observed in depression
(Schafer, 1999). Many of the SSRI’s available, such as fluoxetine or Nefazodone, have
been clinically approved for use during the postpartum period (Weier & Beal, 2004).
However, there is still a lack of research on the effects these antidepressant medicines
have during prolonged usage in mothers who elect to breastfeed. Most of the
antidepressant medications are excreted out via the breast milk, and while only a few
reports indicate a maladaptive effect on the infant, there is a lack of research on the exact
effect of the effect on the medication transmitted through the breast milk. Due to these
perceived effects, there seems to be an increasing number of women turning toward
alternative modes of treatment. Herbal supplements present as a potential alternative
treatment for postpartum depression. St. John’s Wort emerges as a common herbal
medication used in the postpartum period to treat PPD. However, on top of the holes in
the FDA regulations of herbal supplements, the efficacy and safety of St. John’s Wort
may pose a health risk to both the mother and the baby. A comparison between the
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mechanism and the potential interactions of St. John’s Wort and Prozac (fluoxetine) can
help us elucidate a proper way to regulate their usage.
Non-Pharmacological Therapies for PPD
St. John’s wort (SJW) is a common herb often used to treat mild to moderate
depression, in place of other pharmaceutical medications such as SSRI’s. Some women
opt to take SJW rather than a pharmaceutical drug in the postpartum period, citing that
the use of this supplement may be safer because it is thought not to affect the breast milk
as much. In vivo studies indicate that extracts of Hypericum perforatum, what is
commercially known as SJW, serves as an effective treatment for symptoms associated
with mild. However, the pharmacological mechanism for SJW is unknown, due to a
complex mixture of compounds in this supplement and the variability in its purity across
brands(Butterweck & Schmidt, 2007; Linde, 2009).
Initially, the mechanism of this herbal supplement was hypothesized to induce the
inhibition of both type A and B monoamine oxidase (MAO), which are responsible for
the catabolism of biogenic amines. However, while MAO inhibitors are present, this has
been proven to be a minor effect and it doesn’t constitute the whole mechanism employed
by SJW (Butterweck, 2003; Butterweck & Schmidt, 2007).
The leading theory now suggests that Hyperforin, a major active constituent of
SJW, unselectively inhibits the reuptake of neurotransmitters such as serotonin and
dopamine. While the exact mechanism remains unclear, SJW is hypothesized to
indirectly decrease the reuptake of neurotransmitters by changing the permeability of the
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Na+/H+ channels to increase intracellular Na+ levels. Normally, in a neuron, which is a
specialized nerve cell in the body, there is a net negative charge in the membrane
potential. For this cell to transmit a signal, a flow of different ions, such as Na+, K+, and
Ca2+, fluctuates to flip the charge from an overall negative charge to a positive charge.
The ability of a neuron cell to create this change allows for the cell to function and rely
that message on to other cells. The reuptake system of serotonin is inhibited by the influx
of sodium, thus, hyperforin non-selectively inhibits this system, which is a mechanism
similar to that of SSRI’s. (Butterweck & Schmidt, 2007; Carlo, Borrelli, Ernst, & Izzo,
2001; Linde, 2009; Singer, Wonnemann, & Muller, 1999). While Hyperforin currently
remains as the main mechanism for the effects of SJW, there could be additive effects
from the other active constituents.
Pharmacological Therapies for PPD
In terms of pharmacological methods, pp to 35% of women use psychotropic
medications during pregnancy and in the postpartum period. One of the most commonly
prescribed psychotropic medicine during pregnancy is Prozac, drug apart of the larger
family of SSRI’s. The widespread usage of these medications Prozac and other SSRI’s
readily passes through the placental barrier during pregnancy and diffuses into the
breastmilk because of their relatively hydrophobic structures. This leads to discussions
about the safety of these medications not only for maternal health but also how these
drugs can affect infant neurobehavior or induce potential teratogenic effects in utero.
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Prozac, like most SSRI’s, inhibit the molecules responsible for the reuptake of
neurotransmitters such as serotonin, leading to an increase in concentrations of these
molecules at the synaptic cleft (Zeskind & Stephens, 2004).
Despite different chemical compositions, SJW and Prozac employ similar
mechanisms to modulate the symptoms of PPD. Hyperforin, the major active component
in SJW, and Prozac, which is classified as an SSRI, modifies the levels of
neurotransmitters such as serotonin by altering the activity of the enzymes responsible for
the reuptake of these molecules. The etiology of PPD, similar to other mood disorders,
draws from multiple variables including hormonal and biochemical changes within the
body and social environments. The use of medications such as SJW and Prozac helps
curb the clinical symptoms on a biological level.
Risks/Interactions Associated with Nonpharmacological Methods
Due to several active components, SJW may interact with different herbal
supplements and pharmaceutical drugs when taken in tandem. There are two main types
of drug-drug or herb-drug interactions: pharmacokinetic interactions, which refers to drug
absorption, distribution, metabolism, and excretion and pharmacodynamic interactions,
which refers to the relation between the concentration of the substance and its effect
(Pharmacokinetics, 1985). One of the most pertinent interactions revolves around
pharmacokinetic interactions with Cytochrome P450 (CYP), a superfamily of enzymes
crucial for the metabolism of drugs and detoxification of chemicals. SJW is a known
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inducer of CYP enzymes. (Lin & Lu, 1998; Thompson, 1839). Many different drugs and
compounds interact with the mechanism of CYP enzymes within the body and because
SJW alters the activity of these enzymes, it can modulate the effects of other drugs. For
example, SJW significantly reduces the pharmacological effects of Warfarin, a common
blood thinner because the induction of the CYP enzymes leads to increased clearance of
the drug. This leads to serious health risks because it increases the likelihood of
developing blood clots that leads to DVT or stroke. Similarly, studies indicate that SJW
changes the levels of other drugs such as anti-HIV drugs, antiepileptic drugs,
hypoglycemic drugs, benzodiazepines, among other classes of drugs (Borrelli & Izzo,
2009; Thompson, 1839).
Interestingly, CYP enzymes also play a major role in the formation and
metabolism of estrogen within the body. Aromatase, a specific CYP enzyme, mediates
the synthesis of estrogen and the management of the oxidative states of estrogen relies on
another set of CYP enzymes. Drugs that induce CYP enzymes may affect increase the
hydroxylation of estradiol, hence changing the activity of estrogen in the body. These
changes increase the risk for the development and the persistence of PPD in mothers.
While this area remains less studied, SJW, due to its influence on CYP enzymes may
change the symptoms of PPD by altering the levels of estradiol (Martucci & Fishman,
1993).
Risks/Interactions Associated with Pharmacological Methods
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Prozac also exhibits inhibitory action against multiple isoforms of the CYP
enzymes. The inhibition of these enzymes leads to pharmacokinetic features such as a
decrease in clearance of secondary drugs, precipitation of more severe side effects, and
an increase in the likelihood of toxicity. Prozac, when taken in tandem with other SSRI’s
or other antidepressants, can cause a significant surge in serotonin levels, leading to
serotonin syndrome. The inhibition of CYP also alters the metabolism of larger classes of
drugs including cardiovascular drugs and other SSRI’s. On the other hand, Prozac has
also been shown to blocking the conversion of drugs into their active components. This
specific SSRI prevents the conversion of codeine and tramadol, two common analgesic
drugs, into their active components. This significantly reduces the efficacy of analgesic
drugs, causing patients to experience increased pain (Gillman, 2005).
In addition to maternal effects, the ability of Prozac to diffuse across the placental
barrier and the breastmilk exposes infants to these same effects. Exposed infants
experience an elevation in levels of serotonin, which can cause a wide variety of
physiological symptoms such as more generalized erratic motor activity and tremors
(Zeskind & Stephens, 2004). The potent interactions between Prozac with other SSRI’s
and substances warrants careful regulation by the FDA.
While proven to be relatively effective, these medications are not without
significant risks. Due to their similar mechanisms, SJW and Prozac alter the clearance of
other drugs by influencing the activity of CYP, leading to impaired function or an
exacerbation of symptoms. It remains imperative to report usage of both pharmaceutical
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drugs, but also herbal medications to healthcare providers. This allows physicians to
modulate possible interactions with other medications.
Comparing the Preparation and Regulation of SJW and Prozac
Despite their similarities in function and effect, these SJW and Prozac drastically
differ in terms of their preparation methods and regulation. Prozac falls under the
umbrella of pharmaceutical drugs, which requires much stricter regulations on the
concentrations of the active component present. In contrast, SJW and other herbal
medications operate under lax regulations. The concentrations of components in SJW are
not regulated, varying depending on the preparation style. Typically, air-dried H.
perforatum L. flowers and buds are soaked in 60%-80% methanol for approximately 30
minutes to extract out the lipophilic components found in the flower. The identified
components in the final product of SJW fall under several categories:
naphthodianthrones, flavonoids, hyperforin, and water-soluble components. The
concentration and proportions of each constituent vary depending on the duration,
harvesting, a light exposure environment (Butterweck & Schmidt, 2007), hence leading
to great variability in products with a lack of FDA oversight. Different brands of SJW can
contain different substituents, which can alter the effect of other drugs and increase the
risk for unforeseen interactions. With so many prominent similarities, the regulation of
both substances should be altered to mirror each other, thus decreasing the associated
risks of interactions with other medications.
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Chapter 4.2: The Complexity of Lactation: Pharmacological and Herbal Therapies
to Treat Insufficient Milk Supply
Biochemical Changes Involved in Lactation
A major component of the postpartum period revolves around breastfeeding.
Studies indicate that breastfeeding is the optimal form of nutrition for infants, providing
both short term and long-term benefits to the baby. These benefits include immunological
effects and decreased risks for diseases such as gastroenteritis, obesity, and type I and II
diabetes. Breastfeeding also shows signs of enhancing the maternal-fetal emotional bond.
Overall, breastfeeding provides significant benefits to the mother and provides the best
health, psychological, and developmental outcomes for the infant. However, the duration
of exclusive breastfeeding and lactation by the mother remains varied due to many
different circumstances (Conover & Buehler, 2004; Mannion & Mansell, 2012). The
development and secretion of milk by the mother relies on biochemical changes in the
body.
Mammary glands, which are essentially modified sweat glands modulated by the
endocrine system, plays a major role in both lactation and secretion. Lactocytes, milkproducing cells, line the alveoli of the mammary gland, located within the breast and
serve as the main site of milk production. The blood capillaries that surround the alveoli
of the gland provides a system for substrates such as vitamins and glucose to diffuse
across the cell membrane of the lactocytes to be integrated into milk components.
Interestingly, while the same basic components of the milk remain constant, diet plays a
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huge role in dictating the energy content of the milk as well as the vitamin and mineral
content (Hoehn & Marieb, 2016; Kent, 2007). While the vascularization of this area
allows for easy diffusion of milk components and vitamins, it also makes the diffusion of
lipid-soluble substances such as herbal supplements easier.
Lactogenesis I and II
Lactogenesis or the production of milk secretions is mediated primarily by
prolactin, a hormone secreted by the anterior pituitary gland. The main steps in
lactogenesis can be summed up into two main stages lactogenesis I and lactogenesis II.
The first stage typically begins between weeks 16 and 22. During this phase, the
mammary glands begin development (Kent, 2007; Zapantis, Steinberg, & Schilit, 2012).
The second stage, or lactogenesis II, typically occurs immediately after birth.
Characteristic of significant milk production and secretion, this phase typically relies on
fluctuations in the concentrations of certain pituitary hormones. A significant increase in
prolactin, insulin, and adrenal cortisol in combination with a progesterone withdrawal in
the postpartum period allow for the activation of copious milk secretions (Kent, 2007).
This change is typically noted by a sudden feeling of fullness in the breasts.
Biochemical Changes Involved with Secretion
Another prominent hormone apart of this system involves oxytocin, which also
causes uterine contractions to initiate and propagate the birthing process. In a process
referred to as “let down,” a spike in oxytocin influences the expulsion of milk from the
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breast. Suckling or stimulation of the nipple area activates sensory afferent neurons,
sending a signal that prorogates to the anterior pituitary gland. The stimulation of this
gland causes the release of oxytocin. Once this hormone reaches the mammary gland, via
the bloodstream, oxytocin acts on the contractile cells surrounding the alveoli causing the
release of breast milk. While direct stimulation via sucking by the infant remains the
primary trigger for this response, schedule of feeding or even merely the sight of the baby
can cause this reflex to activate. Thus, hormonal imbalance, especially in the levels of
oxytocin may result in alterations of the release of the milk (Hoehn & Marieb, 2016;
Newton & Newton, 1950).
Herbal Supplement Usage during Lactation
A common problem during the breastfeeding stage, which can last over a year
postpartum, revolves around perceived insignificant milk supply. Most often, this issue
results from improper breastfeeding techniques, but can also be the product of maternal
hormone imbalance or deficiency in the breast tissues. If breastfeeding techniques, such
as latching, are ruled out, the use of galactagogues can be used to increase the production
or flow of milk. Galactagogues can include foods, herbal medications, and
pharmaceutical drugs (Hoehn & Marieb, 2016; Westfall, 2003; Zapantis et al., 2012).
Hundreds of plant species have been used to increase milk production, however, despite
centuries of usage by women worldwide, most of these substances remain unproven in a
lab or clinical setting.
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Table 4: Common herbal medications used during the lactation period.1 (Yildirim,
Desdicioglu, Kara, & Yavuz Avsar, 2016), (Mannion & Mansell, 2012) 2 (Westfall,
2003), (Mannion & Mansell, 2012), 3,4 (Mannion & Mansell, 2012).
Herbal Supplement

Reason for
Use
To stimulate
the
development of
breast milk

Benefits

Interactions

Fennel 2

Expectorant,
Upper
respiratory
tract infection,
antispasmodic,
galactagogue

Digestive
aid, mild
estrogenic
properties

Potential
interactions
with
anticoagulant
medication
and
antidiabetic
medicine
Can interact
with
anticonvulsant
medications

Blessed Thistle 3

Stimulates
menstruation,
antidiarrheal,
expectorant,
galactagogue

Nausea,
vomiting,
diarrhea,
contact
dermatitis

May interfere
with antacids,
H2
antagonists,
proton pump
inhibitors,
insulin

Anise 4

Expectorant,
antispasmodic,
antiseptic,
antiflatulence

Seizures

Interactions
with
anticoagulants,
MAO
inhibitors, and
oral
contraceptives

Fenugreek 1

Associated
Risk
Stimulates Hypoglycemic
oxytocin
effects,
secretion
hepatoxicity,
to help
diarrhea
induce
labor
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Seizures,
nausea,
pulmonary
edema

Out of the hundreds of herbal galactagogues, the most commonly used one is
Fenugreek. Historically, this plant, originating from India and Northern Africa has been
used to treat a range of aliments from induction of labor to digestion to cough (Ulbricht et
al., 2007). The preparation of this herbal supplement typically includes the addition of
saponin, alkaloids, amino acids, coumarin, among other ingredients (Abebe, 2002). Due
to minimal regulation by the FDA, the concentrations of these components vary, altering
the efficacy and safety of fenugreek supplements.
The main mechanism of Fenugreek remains unknown and poorly documented,
moreover, the active ingredients have not been identified. Scant clinical trials have yet to
establish the safety of efficacy of Fenugreek usage during pregnancy or the lactation
period. It is hypothesized that Fenugreek stimulates sweat production, which may affect
the function of the mammary glands, which are essentially just modified sweat glands.
Fenugreek might also contain estrogenic activity. This herbal supplement contains
estrogen-like compounds that can increase the levels of phytoestrogens, dietary estrogens
that can potentially bind to estrogen receptors, altering the functionality of the endocrine
system (Gabay, 2002; Mortel & Mehta, 2013).
Risks and Interactions Associated with Nonpharmacological Methods
Typically, Fenugreek is well tolerated with no serious side effects. However,
when taken with some pharmaceutical drugs, this herbal supplement may exacerbate the
effect of medications when taken in tandem. Fenugreek may interfere with hormone
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therapy, due to its estrogen like-components. Moreover, studies have shown that
Fenugreek may interfere with the function of diabetic drugs such as insulin as well as
corticosteroids. 4-hydroxyisoleucine, one of the active components in Fenugreek, may
directly stimulate insulin release, which complicates the metabolism of patients with
diabetes and their insulin dosage (Mills et.al., 2006).
Pharmaceutical Drugs for Milk Production
Metoclopramide and domperidone constitute the main drug therapies currently
available for the stimulation of milk production. Both of these substances act by acting as
a dopamine antagonist, which subsequently increases prolactin release. A surge in
prolactin signals for increasing production of milk, however, this method only addresses
underlying hormone imbalance that may cause a decrease in milk production. Once other
factors, particularly poor latching techniques, are addressed, physicians can prescribe a
regiment with metoclopramide and domperidone to promote milk production. (Gabay,
2002; Osadchy et.al., 2012; Westfall, 2003; Zapantis et al., 2012). Case studies indicate
that the usage of metoclopramide shows an increase in a decrease in milk sodium
concentration, but more prominently, a significant increase in both prolactin levels in the
blood and a prominent increase in daily milk production (Gabay, 2002).
In comparison, Domperidone utilizes a similar mechanism as a dopamine
antagonist, this increasing the prolactin levels in the blood. However, rather than having
central pharmacologic effects, Domperidone has a larger effect on the periphery
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dopamine release system. Due to lower lipid solubility and a larger molecular structure,
Domperidone exhibits a decreased ability to cross the blood-brain barrier. With a lower
diffusion rate, this drug seems to exhibit less influence on motor neuron function
compared to Metoclopramide and less overall diffusion into the breast milk. While
domperidone is typically intended for use as an antiemetic to treat reflux disease, this
medication is often used as a galactagogue without the presence of serious side effects
(Gabay, 2002; Mannion & Mansell, 2012).
Risks/Interactions Associated with Pharmacological Methods
In 2004, the FDA issued a warning against the usage of Domperidone as a
galactagogue. Citing reports of arrhythmia, QT prolongation, and hypokalemia, the U.S.
bans the usage of this drug for milk enhancement. Domperidone remains available
internationally and is embraced by other countries as an effective therapy for milk
production (Osadchy et al., 2012). Domperidone has been shown to be a weak inhibitor
of CYP3A, a specific enzyme apart of the CYP superfamily important in the clearance of
certain drugs. Thus, Domperidone may increase the exposure to drugs cleared by CYP3A
(Chang et.al., 2010).
Metoclopramide, a central dopamine antagonist, may cause drowsiness, fatigue,
insomnia, depression, and pseudo-Parkinsonism. Due to its ability to pass into the breast
milk, prolonged clearance of this drug into infants result in high serum levels, increasing
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the risk for methemoglobinemia (increased methemoglobin levels in the blood) (Mannion
& Mansell, 2012).
Comparison Between Pharmacological Drugs and Herbal Supplements
In comparison to pharmacological therapies, fenugreek along with many other
galactagogues presents with questionable efficacy for stimulating the production of
breastmilk. With little clinical evidence, the usage of herbal galactagogues propagates
through individual accounts and case studies. Moreover, most of these herbal products
operate using an unknown mechanism. In contrast, pharmaceutical drugs, mainly
Domperidone and metoclopramide, presents strong clinical and mechanistic evidence for
efficacy in stimulating milk production. Despite their differences, active components in
both herbal and pharmaceutical galactagogues can directly conflict with other
medications to cause adverse side effects. However, similar to the situation between the
regulation of herbal supplements and pharmaceutical drugs to treat PPD, the regulation
between substances used for stimulation of milk production also shows distinct
discrepancies. Herbal supplements require no premarket approval, empirical support, nor
do they require a prescription to obtain. In contrast, pharmacological drugs are required
to complete several rounds of clinical trials before being approved for distribution. These
drugs are also required to adhere to rigid production standards and labeling requirements.
As mentioned earlier in this chapter, herbal supplements and pharmacological can induce
a whole host of biochemical interactions, leading to physiological symptoms.
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Chapter 5: Empowering Women to make the Best Treatment Choice During
Pregnancy, Birth, and Beyond
While there seems to be a social distinction between herbal supplements and
pharmacological treatments, I hope that through this thesis, I effectively challenge this
notion. Scientific data suggests that herbal supplements can employ a similar
physiological effect and induce interactions with other substances, just like any
pharmacological drug. Yet, the lack of government regulation and the skewed media
presentation of herbal supplements buries the associated risks and effects.
After stepping through how the hormonal fluctuations impart a multitude of
symptoms and how medications, both pharmacological and herbal, influence hormonal
and biological homeostasis, the overarching question is should herbal supplements be
used or even recommended. In other words, do the benefits of herbal supplements
outweigh the risks? I argue that in most cases, the risks actually outweigh the benefits.
There is a lack of reliable information and the risks of taking these supplements remain
widely unknown. Especially for women who must balance their own health with their
baby’s health, this poses a huge health dilemma. Researchers and providers alike should
work to close the gaps in knowledge and provide women with a solid scientific
foundation to make informed decisions on medication regiments.
While I cannot offer definitive answers or methods to solve this issue, I believe
that there are two main directions we can take to advocate for change in the regulation
and perception of herbal medications. This shift needs to be initiated by health care
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professionals in the examination room. Healthcare providers need a higher and more
global understanding of women’s current perspective on using alternative medicine. With
a more holistic point of view, physicians can change the culture around herbal medicine
by creating a safe space for patients to voice questions or concerns. In many ways, this
reflects the Jesuit mission of Cura Personalis, a Latin term that translates to “care for the
entire person.” Extending on the Hippocratic oath of “do no harm”, under Cura
personalis, doctors are responsible for not only harm reduction but also acknowledging
and treating all aspects of the person. Alternative and herbal medicine is deeply ingrained
in many different cultures and thus plays an important part in a patient’s choices and
views.
The second avenue that can change the perception of alternative medicine lies
within scientific communication, particularly the media portrayal of these substances. A
quick Google search yields thousands of results, with most of the top hits consisting of a
number of blog posts with personal stories on the success of herbal supplements curing
different diseases or symptoms. Often times, these anecdotal stories portray herbal
supplements as completely harmless. While there are proven merits to certain herbal
supplements, many of them, as denoted earlier have serious side effects. Scientists can
take on a larger role in educating the general public. Publishing empirically supported
articles in different magazines and journals help provide a more accurate portrayal of
herbal supplements and can help raise awareness of the lack of information on their
mechanism.
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The use of herbal medicine and alternative medicine in the U.S. bisects both
physiology and biochemistry with cultural influences such as tradition. The dialect and
communication between researchers, health care providers, and patients are critical in
navigating the different paths possible. We shouldn’t shy away from herbal supplements
and alternative medicine, but rather, we should encourage conversation about them. I
hope that this thesis serves as a tool to spark the conversation.
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